Oral squamous cell carcinoma (OSCC) is one of the most common cancers of the oral cavity and remains associated with high rates of recurrence and treatment failure. A growing body of evidence indicates that cancer cells can reprogram their metabolism to support tumor growth and resist therapy. Among these metabolic alterations, glutamine metabolism has emerged as a promising therapeutic target. This project will investigate whether inhibiting glutaminolysis, a key pathway involved in glutamine utilization, can improve the effectiveness of cisplatin, one of the standard treatments for OSCC. The study will be conducted using three-dimensional (3D) tumor models, which more closely reproduce the biological and metabolic characteristics of human tumors than conventional cell culture systems. In addition, the project will explore metabolic biomarkers associated with treatment response, aiming to identify factors that may predict which tumors are more likely to benefit from this therapeutic approach. The results will contribute to a better understanding of metabolic vulnerabilities in oral cancer and may support the development of more effective and personalized treatment strategies.